High Fidelity RNA Editor Development & Studies Supporting the World’s First CRISPR/RNA-Targeting Therapy, HG202, for Patients with Neovascular Age-Related Macular Degeneration

• Identification, protein engineering and characterization of high fidelity hfCas12Y
• The opportunity and advantages or RNA editing for Neovascular Age-Related Macular Degeneration (nAMD)
• The molecular composition, mechanism of action, and preclinical animal studies of RNA editor HG202

Speakers:

TJ Cradick

Chief Technology Officer

HuidaGene Therapeutics